<DOC>
	<DOCNO>NCT03013101</DOCNO>
	<brief_summary>This multi-center , open-label , phase 2 study evaluate humanize anti-PD-1 antibody JS001 , monotherapy patient locally advance metastatic melanoma fail routine systemic treatment .</brief_summary>
	<brief_title>Safety Efficacy Recombinant Humanized Anti-PD-1 mAb Patients With Locally Advanced Metastatic Melanoma</brief_title>
	<detailed_description>This multiple-center , open-label , phase 2 study evaluate humanize anti-PD-1 antibody JS001 , monotherapy patient locally advance metastatic melanoma fail previous routine systemic treatment . Patients inject JS001 3mg/kg every 2 week disease progress unacceptable toxicity occur . Response assessment conduct every 8 week .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Male Female age 18 old eligible ; Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 1 ; Histologic diagnosis locally advance metastatic melanoma , ocular melanoma exclude , overall rate mucousal melanoma 25 % . Have fail least 1 prior routine regimen advance disease . Providing tumor specimen ( test expression PD L1 infiltrate lymphocyte ) ; documentary evidence BRAF mutation status ; At least 1 measurable lesion ( 1 measurable lymph node lesion exclude ) ( routine CT scan &gt; =20mm , spiral CT scan &gt; =10mm , prior radiation measurable lesion ) Predicted survival &gt; =3 month ; Brain meningeal metastasis must dispose surgery radiation , stable clinically least 3 month ( prior systemic steroid allow , concurrent administration systemic steroid study drug exclude ) . Screening laboratory value must meet follow criteria（within past 14 days） : hemoglobin ≥ 9.0 g/dL ; neutrophil ≥ 1500 cells/ µL ; platelet ≥ 100 x 10^3/ µL ; total bilirubin ≤ 1.5 x upper limit normal ( ULN ) ; aspartic transaminase ( AST ) alanine transaminase ( ALT ) ≤ 2.5 x ULN without , ≤ 5 x ULN hepatic metastasis ; serum creatinine ≤1╳ULN，creatinine clearance &gt; 50ml/min ( CockcroftGault equation ) PT/INR , aPTT≤1.5 x ULN ; Without systemic steroid within past 4 week Males female childbearing potential must : agree use use reliable form contraception ( eg , oral contraceptive , intrauterine device , control sex desire , double barrier method condom spermicidal ) treatment period least 12 month last dose study drug . Must read , understood , provide write informed consent voluntarily . Willing adhere study visit schedule prohibition restriction specify protocol . Prior treatment antiPD1/PDL1/PDL2 antibody ; Hypersensitivity recombinant humanize antiPD1 monoclonal Ab component . Prior treatment mAb within past 4 week . Prior antitumor therapy ( include corticosteroid immunotherapy ) participation clinical trial within past 4 week , recover toxicity since last treatment ; Pregnant nursing ; Positive test HIV , HCV , HBsAg HBcAb positive test HBV DNA ( &gt; 500IU/ml ) History tuberculosis ; Patients active autoimmune disease document history autoimmune disease , history syndrome require systemic steroid immunosuppressive medication , hypophysitis , pneumonia , colitis , hepatitis , nephritis , hyperthyroidism hypothyroidism . Severe , uncontrolled medical condition would affect patient ' compliance obscure interpretation toxicity determination adverse event , include active severe infection , uncontrolled diabetes , angiocardiopathy ( heart failure &gt; class II NYHA , heart block &gt; II grade , myocardial infarction , unstable arrhythmia unstable angina within past 6 month , cerebral infarction within past 3 month ) pulmonary disease ( interstitial pneumonia , obstructive pulmonary disease symptomatic bronchospasm ) . Evidence active CNS disease . meningeal carcinomatosis ; Prior treatment bone marrow stimulate factors，such CSF ( colony stimulate factor ) , EPO ( erythropoietin ) , within past 2 week Prior live vaccine therapy within past 4 week . Prior major surgery within past 4 week ( diagnostic surgery exclude ) . Psychiatric medicine abuse without withdrawal , history psychiatric illness . Prior malignancy active within previous 5 year except locally curable cancer apparently cure , basal cell skin cancer carcinoma situ cervix . Underlying medical condition , Investigator 's opinion , would increase risk study drug administration obscure interpretation toxicity determination adverse event .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>anti-PD-1 monoclonal antibody</keyword>
	<keyword>advanced</keyword>
	<keyword>metastatic</keyword>
	<keyword>melanoma</keyword>
</DOC>